adct-601
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 21, 2018 (NCT03700294)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- pyrrolobenzodiazepine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05389462 | Phase 1 | Jul 13, 2022 | ADC Therapeutics SARL |
| NCT03700294 | Phase 1 | Dec 21, 2018 | ADC Therapeutics SARL |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADC Therapeutics SARL | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1